Date: 2011-06-14
Type of information: R&D agreement
Compound: monoclonal therapeutic antibodies for use in polyvalent vaccines against antibiotic-resistant bacterial infections
Company: Antitope (UK) IMMIH-University of Cologne (Germany)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: Antitope has announced a research agreement with the Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany (“IMMIH“) for the generation of monoclonal therapeutic antibodies for use in polyvalent vaccines against antibiotic-resistant bacterial infections. Under this agreement, Antitope will apply its Composite Human Antibody™technology to humanize three murine monoclonal antibodies. The resulting humanized antibodies will be devoid of T cell epitopes with a reduced risk of clinical immunogenicity.
Financial terms:
Latest news:
